KoACT Collagen Boosts BMD

INDUSTRY, Calif.AIDP Inc. released initial results of a double blind, placebo-controlled clinical trial of KoACT, led by Florida State University. According to the new data, published in Journal of Food and Nutritional Disorders, the patented collagen compound may reverse bone loss in osteopenic postmenopausal women.

In the trial, 40 women received either calcium or KoACT for three months daily. Scientists measured bone metabolism and bone mineral density (BMD) of the lumbar spine and total body at baseline and after three months. The KoACT group experienced a significant increase in total body bone mineral density and bone-specific alkaline phosphatase, which indicated bone formation.

The clinical trial results strongly suggest that KoACT® provides additional benefits to strengthen the bone, instead of addressing calcium deficiency only as most of the currently available bone supplements. It is a preferred preventative measure to combat bone loss," said Jennifer Gu, PhD., AIDP director of research and development.

Collagen is just one ingredient finding scientific success in the bone market. Learn more in the INSIDER feature "Bone, Joint Ingredients Find Synergistic Strength."